Pharmaron Beijing Co Ltd (3759)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 20 Oct 2026
Key indicators
| Last close | HKD 27.12 |
|---|---|
| 52-week range | 14.29 – 34.86 |
| Return, 1 month / 3 months | −7.7% / +14.8% |
| Return, 1 year / 3 years | −1.9% / +67.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 39 |
| Volatility (1 year) | 51.1% |
| Worst drawdown (1 year) | -42.7% |
| Average daily value traded | 230.17M HKD |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pharmaron Beijing is a contract research organisation that helps pharmaceutical and biotechnology companies develop new medicines. It provides laboratory research services in chemistry and biology, carries out preclinical safety testing, and supports clinical development programmes. The company also manufactures drug intermediates and active pharmaceutical ingredients for its clients. Pharmaron is based in Beijing, China, and works with customers around the world who are developing treatments for a range of diseases.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 3759, and the price on this page is in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pharmaron Beijing Co Ltd (3759) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 27.12 on 20 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 240 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.9% and over the last three months it rose 14.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.8% | ||
| From 52-week high | -19.9% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 14.8% | ||
| 6-month return | 29.2% | ||
| 12-month return, skipping the last month | 6.3% | ||
| Stability (higher is calmer) | 58 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 51.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -42.7% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 230.17M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 33 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −11.2% |
|---|---|
| 1 month | −7.7% |
| 3 months | +14.8% |
| 6 months | +29.2% |
| 1 year | −1.9% |
| 3 years | +67.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 29.86 / 22.45 |
|---|---|
| Golden / death cross (60 days) | Golden, 45 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.82 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Jul 2026 | HKD 0.2299 |
| 4 Jul 2025 | HKD 0.2188 |
| 27 Jun 2024 | HKD 0.2199 |
| 18 Jul 2023 | HKD 0.4929 |
| 6 Jun 2022 | HKD 0.7924 |
| 1 Jun 2021 | HKD 0.3626 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.